As a result of prostate-specific antigen (PSA) testing and an ageing population, prostate cancer (PCa) has become the most commonly diagnosed form of non-cutaneous (internal) cancer in men, accounting for 26% of all new male visceral cancer cases in the UK, with over 47,000 new diagnoses every year [5]. The gene discussed is KLK3; the disease is posterior cortical atrophy.